AI assistant
Sending…
Cartesian Therapeutics, Inc. — Director's Dealing 2025
Jan 6, 2025
33483_dirs_2025-01-06_977be711-0b13-420a-a062-e7621f8bf75f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2025-01-02
Reporting Person: BARABE TIMOTHY C (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-01-02 | Common Stock | A | 2600 | — | Acquired | 24366 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-01-02 | Stock Option (Right to Buy) | $16.93 | A | 7800 | Acquired | 2035-01-01 | Common Stock (7800) | Direct |
Footnotes
F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2026.
More from Cartesian Therapeutics, Inc.
Capital/Financing Update
2026
May 26
Share Issue/Capital Change
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Earnings Release
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 28
Board/Management Information
2026
Mar 30
Major Shareholding Notification
2026
Feb 5
Investor Presentation
2026
Jan 9
Director's Dealing
2026
Jan 8
Director's Dealing
2026
Jan 8